What one share of Capricor Therapeutics holds
Capricor Therapeutics, Inc. is a biotechnology company focused on the development and potential commercialization of cell and exosome-based therapeutics for the treatment of Duchenne muscular dystrophy (“DMD”), a rare genetic disorder characterized by progressive muscle degeneration and premature death, as well as other diseases with significant unmet medical need.
Capricor Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.47 |
|---|---|
| Capex (buildings and equipment) | $0.21 |
| Free cash flow | −$2.19 |
| Cash and investments | $0.36 |
| Book value | $4.24 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2010 | — | −$1.90 | $0.00 | −$7.78 | — | — |
| 2012 | $0.20 | −$2.08 | $0.01 | −$2.21 | — | $4.73 |
| 2013 | $0.48 | −$8.47 | $0.05 | −$5.90 | — | −$0.46 |
| 2014 | $4.09 | −$5.31 | $0.14 | $0.68 | — | −$5.34 |
| 2015 | $3.47 | −$8.09 | $0.08 | −$6.88 | — | −$0.63 |
| 2016 | $2.16 | −$10.14 | $0.10 | −$7.90 | — | −$1.87 |
| 2017 | $1.00 | $0.91 | $0.01 | −$5.32 | — | $4.27 |
| 2018 | $0.57 | −$5.17 | $0.11 | −$4.82 | — | $1.47 |
| 2019 | $0.27 | −$2.06 | $0.00 | −$1.84 | — | $1.31 |
| 2020 | $0.02 | −$0.88 | $0.04 | −$0.68 | — | $1.37 |
| 2021 | $0.01 | −$0.87 | $0.05 | −$0.78 | — | $1.30 |
| 2022 | $0.10 | −$1.18 | $0.08 | $0.12 | — | $0.47 |
| 2023 | $0.94 | −$0.83 | $0.05 | −$1.00 | — | $0.73 |
| 2024 | $0.63 | −$1.15 | $0.03 | −$1.17 | — | $3.19 |
| 2025 | $0.00 | −$2.26 | $0.06 | −$1.56 | — | $5.33 |
Common questions about Capricor Therapeutics
How much does one share of Capricor Therapeutics earn?
Over the last 12 months, Capricor Therapeutics lost $2.47 for each share.
Does Capricor Therapeutics pay a dividend?
Capricor Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Capricor Therapeutics’s book value per share?
Capricor Therapeutics’s book value is $4.24 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Capricor Therapeutics have?
Each share of Capricor Therapeutics has $0.36 of cash and investments, as of June 30, 2026.
What is Capricor Therapeutics’s free cash flow per share?
−$2.19 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Capricor Therapeutics bought back shares?
Capricor Therapeutics’s share count rose about 8265% from 2010 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.